Recent News Releases
For investor-related news, see our ASX releases here.
- Sep 13, 2022
The new facility, once fully open later this calendar year, will be CSL's largest R&D site under one roof, with more than 500 team members working in a state-of-the-art facility offering access to...
Sep 13, 2022CSL Seqirus to Highlight Commitment to Influenza Protection with More than 20 Data Presentations at OPTIONS XI
CSL Seqirus, a part of CSL Limited (ASX:CSL), today announced new data will be presented at the Options for the Control of Influenza (OPTIONS XI) conference taking place September 26-29, 2022 in...
Sep 8, 2022Orphan Drug Designation granted for etranacogene dezaparvovec, CSL’s gene therapy for haemophilia B, by the Therapeutics Goods Administration
TGA’s designation underscores CSL’s promise to develop and deliver a truly unique portfolio of patient-focused therapies for people with rare and serious medical conditions
Aug 22, 2022CSL Vifor and Travere Therapeutics announce EMA has accepted for review the Conditional Marketing Authorization application for sparsentan for the treatment of IgA Nephropathy
A review decision by the European Medicines Agency (EMA) is expected in the second half of 2023 If approved, sparsentan will be a first-in-class treatment to address the significant unmet medical...
Aug 22, 2022
U.S. District Court for the District of Delaware rules Teva Pharmaceuticals infringes VFMCRP patent Disputes with all other Abbreviated New Drug Application (ANDA) filers regarding Velphoro® have...
Aug 19, 2022
Kapruvia® (difelikefalin) is the first and only therapy approved through consortium filing for the treatment of chronic kidney disease (CKD)-associated pruritus in hemodialysis patients Therapy...
Aug 18, 2022
With this recommendation, eligible patients in England, Wales and Northern Ireland will be able to access the first orally administered therapy for GPA/MPA, two main forms of ANCA-associated...
Aug 17, 2022CSL Announces Positive Top-Line Phase 3 Results for Garadacimab as Preventive Treatment in Patients with Hereditary Angioedema (HAE)
KING OF PRUSSIA, PA CSL is on track to file for regulatory approvals next year and will present full data set at an upcoming scientific congress 17 Aug 2022 Global biotechnology leader CSL...
Aug 16, 2022
CSL Limited (ASX: CSL) Today, CSL advances its vision for a more sustainable future by setting new, tangible targets for carbon emissions reductions. As part of the company's broader...
- Aug 10, 2022
All business units will incorporate CSL name and branding to signify one company MELBOURNE, Australia, Aug. 10, 2022 /PRNewswire/ -- Global biotech leader CSL today announced that all business...